Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myomesin-1 (MYOM1) is a large, structural protein encoded by the MYOM1 gene that forms an essential component of the M-band in striated muscle sarcomeres[1][3][5]. It cross-links adjacent myosin filaments and connects titin molecules, thereby maintaining the spatial organization and mechanical integrity of the sarcomere during contraction and relaxation. MYOM1 contains fibronectin type III and immunoglobulin-like domains, allowing dimerization and elasticity[1][2][6]. It is involved in mechano-signaling, energy homeostasis, and is critical for proper sarcomere assembly and muscle function[2][5]. Alternative splicing yields tissue- and disease-specific isoforms such as EH-myomesin, which are implicated in the adaptive response to cardiac stress and early stages of dilated cardiomyopathy[1][2][3]. MYOM1 is not known to be a therapeutic target or druggable protein, but its altered expression or splicing is associated with muscular and cardiac diseases, making it an emerging biomarker for muscle damage and disease progression[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myomesin-1 (MYOM1).